Immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion

Transplantation

Volumn 93, Issue 8, 2012, Pages 777-786

  Goto, Ryoichi ^a   Yamashita, Kenichiro ^a   Aoyagi, Takeshi ^a   Ueki, Shinya ^a   Uno, Motohiro ^a   Oura, Tetsu ^a   Kobayashi, Nozomi ^a   Igarashi, Rumi ^a   Shibasaki, Susumu ^a   Wakayama, Kenji ^a   Hirokata, Gentaro ^a   Shibata, Tomohiro ^a   Zaitsu, Masaaki ^a   Umezawa, Kazuo ^b   Ozaki, Michitaka ^a   Todo, Satoru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Activation induced cell death; Donor specific blood transfusion; Heart transplantation; Nuclear factor kappa B; Regulatory T cells

Indexed keywords

DEHYDROXYMETHYLEPOXYQUINOMICIN;

ACTIVATION INDUCED CELL DEATH; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TRANSFUSION; CELL DEATH; CONTROLLED STUDY; DONOR SPECIFIC TRANSFUSION; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SURVIVAL TIME; T CELL DEPLETION;

ANIMALS; BENZAMIDES; BLOOD TRANSFUSION; COMBINED MODALITY THERAPY; CYCLOHEXANONES; GRAFT SURVIVAL; H-2 ANTIGENS; HEART TRANSPLANTATION; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; NF-KAPPA B; T-LYMPHOCYTES, REGULATORY;

EID: 84859642994     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318248ca5f     Document Type: Article

References (53)

1. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921.
2. Suzuki T, Yamashita K, Jomen W, et al. The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. J Surg Res 2008; 149: 69.
3. Weil R, Israel A. T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes. Curr Opin Immunol 2004; 16: 374.
4. Csizmadia V, Gao W, Hancock SA, et al. Differential NF-kappaB and IkappaB gene expression during development of cardiac allograft rejection versus CD154 monoclonal antibody-induced tolerance. Transplantation 2001; 71: 835.
5. Suzuki J, Morishita R, Amano J, et al. Decoy against nuclear factorkappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 2000; 7: 1847.
6. Finn PW, He H, Ma C, et al. Molecular profiling of the role of the NF-kappaB family of transcription factors during alloimmunity. J Leukoc Biol 2002; 72: 1054.
7. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.
8. Ariga A, Namekawa J, Matsumoto N, et al. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NFkappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277: 24625.
9. Yamamoto M, Horie R, Takeiri M, et al. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008; 51: 5780.
10. Ueki S, Yamashita K, Aoyagi T, et al. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Transplantation 2006; 82: 1720.
11. Wakamatsu K, Nanki T, Miyasaka N, et al. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005; 7: R1348.
12. Kosaka T, Miyajima A, Kikuchi E, et al. The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti- Thy1.1-induced glomerulonephritis in rats. Nephron Exp Nephrol 2008; 110: e17.
13. Umezawa K. Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci 2006; 97: 990.
14. Iwaki Y, Terasaki PI. Donor-specific transfusion. Clin Transpl 1986: 267.
15. Opelz G, Terasaki PI. Prolongation effect of blood transfusions on kidney graft survival. Transplantation 1976; 22: 380.
16. Kingsley CI, Karim M, Bushell AR, et al. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080.
17. Jarvinen LZ, Blazar BR, Adeyi OA, et al. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation 2003; 76: 1375.
18. Davies CB, Madden RL, Alexander JW, et al. Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival. Transplantation 1993; 55: 1107.
19. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.
20. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560.
21. Yamashita K, Ollinger R, McDaid J, et al. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. FASEB J 2006; 20: 776.
22. Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+T cells specific for defined antigens according to CD154 expression. Nat Med 2005; 11: 1118.
23. Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 1997; 100: 3173.
24. Zheng XX, Sanchez-Fueyo A, Domenig C, et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev 2003; 196: 75.
25. Watanabe M, Dewan MZ, Okamura T, et al. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005; 114: 32.
26. Vega MI, Martinez-Paniagua M, Jazirehi AR, et al. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008; 49: 1982.
27. Miyake A, Dewan MZ, Ishida T, et al. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect 2008; 10: 748.
28. Meng Z, Mitsutake N, Nakashima M, et al. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 2008; 149: 5357.
29. Watanabe M, Dewan MZ, Taira M, et al. IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/ Reed-Sternberg cells. Lab Invest 2007; 87: 372.
30. Nishioka C, Ikezoe T, Jing Y, et al. DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin- stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. Immunology 2008; 124: 198.
31. Iwakoshi NN, Mordes JP, Markees TG, et al. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000; 164: 512.
32. Sandner SE, Clarkson MR, Salama AD, et al. Mechanisms of tolerance induced by donor-specific transfusion and ICOS-B7h blockade in a model of CD4+ T-cell-mediated allograft rejection. Am J Transplant 2005; 5: 31.
33. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303.
34. Tone Y, Furuuchi K, Kojima Y, et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008; 9: 194.
35. Wieckiewicz J, Goto R, Wood KJ. T regulatory cells and the control of alloimmunity: From characterisation to clinical application. Curr Opin Immunol 2010; 22: 662.
36. Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126: 375.
37. Kawai M, Kitade H, Mathieu C, et al. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 2005; 79: 1073.
38. Long M, Park SG, Strickland I, et al. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009; 31: 921.
39. Schmidt-Supprian M, Courtois G, Tian J, et al. Mature T cells depend on signaling through the IKK complex. Immunity 2003; 19: 377.
40. Jana S, Jailwala P, Haribhai D, et al. The role of NF-kappaB and Smad3 in TGF-beta-mediated Foxp3 expression. Eur J Immunol 2009; 39: 2571.
41. Gagne K, Brouard S, Guillet M, et al. TGF-beta1 and donor dendritic cells are common key components in donor-specific blood transfusion and anti-class II heart graft enhancement, whereas tolerance induction also required inflammatory cytokines down-regulation. Eur J Immunol 2001; 31: 3111.
42. Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652.
43. Puccetti P, Grohmann U. IDO and regulatory T cells: A role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007; 7: 817.
44. Thompson AG, O'Sullivan BJ, Beamish H, et al. T cells signaled by NF-kappa B- dendritic cells are sensitized not anergic to subsequent activation. J Immunol 2004; 173: 1671.
45. Hernandez A, Burger M, Blomberg BB, et al. Inhibition of NF-kappa B during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches. Hum Immunol 2007; 68: 715.
46. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003; 170: 1304.
47. Aronica MA, Mora AL, Mitchell DB, et al. Preferential role for NFkappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol 1999; 163: 5116.
48. Corn RA, Aronica MA, Zhang F, et al. T cell-intrinsic requirement for NF-kappa B induction in postdifferentiation IFN-gamma production and clonal expansion in a Th1 response. J Immunol 2003; 171: 1816.
49. Corn RA, Hunter C, Liou HC, et al. Opposing roles for RelB and Bcl-3 in regulation of T-box expressed in T cells, GATA-3, and Th effector differentiation. J Immunol 2005; 175: 2102.
50. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8: 837.
51. Iwata D, Kitaichi N, Miyazaki A, et al. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice. Invest Ophthalmol Vis Sci 2010; 51: 2077.
52. Mucida D, Kutchukhidze N, Erazo A, et al. Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 2005; 115: 1923.
53. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.